Mercury Pharmaceuticals

Researchers identify control switch protein that starves tuberculosis bacteria

A protein that acts as a 'control switch,' preventing Mycobacterium tuberculosis from accessing the energy sources it needs to survive, has been identified by researchers at the University of Surrey.

Synthetic protein hybrid offers promising treatment for liver diseases

The research group led by CIC biomaGUNE's Ikerbasque Research Professor Aitziber L. Cortajarena has developed an innovative anti-fibrotic and anti-tumor treatment by binding a synthetic protein to gold nanoclusters (small aggregates of approximately 6 atoms of gold).

Cytoskeletal proteins in the cell nucleus influence brain development

The cytoskeleton gives cells their shape and helps them move. Researchers at Helmholtz Munich and the Ludwig Maximilian University now show that, in neural stem cells, proteins of the cytoskeleton are also found in the cell nucleus, where they can influence developmental programs.

New project aims to systematically map billion cellular interactions

Curtin University projects explore youth health issues in Western Australia

Curtin University Curtin University researchers will examine the 'partygoing' behaviours of young people in regional areas, the use of nicotine pouches and ways to promote physical activity among young people as part of new projects funded by Healthway.

New TRUECAM wrapper makes medical artificial intelligence more trustworthy

Medical artificial intelligence (AI) faces a fundamental challenge: uncertainty quantification. Artificial neural networks are largely unaware of the limits of their training data and can become overconfident when confronted with unfamiliar inputs. Suppose you train a neural network to distinguish among African mammals.

Stockholm3 blood test may offer more accurate prostate cancer detection

Revolutionary protective shoe concept provides increased comfort and minimizes strain

A revolutionary protective shoe concept adapts to the needs of users in a new way and provides increased comfort and minimizes strain.

TRIMTECH Therapeutics brings total seed round to $47 M with additional investment of $14 M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio

TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has raised an additional $14 million in seed funding, bringing the total for the round to $47 million (£35 million).

The menstrual cycle changes heart-rate variability but not strength

Menstrual cycle phases influence heart autonomic regulation, showing HRV variations, yet muscle performance and mood states remain largely unchanged.